(Q37120621)

18 August 2017

1 reference

title

Efficacy and safety of once-daily regimens in the treatment of HIV infection (English)

1 reference

18 August 2017

0 references

Jean-Michel Molina

1

1 reference

PubMed ID

18370438

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

68

1 reference

18 August 2017

5

1 reference

18 August 2017

567-578

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868050-00001

18 August 2017

0 references

cites work

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

1 reference

12 December 2020

Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).

1 reference

12 December 2020

Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence

1 reference

12 December 2020

The Assessing Patients’ Preferred Treatments (APPT-1) study

1 reference

12 December 2020

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen

1 reference

12 December 2020

Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors

1 reference

12 December 2020

Early virological failure with a combination of tenofovir, didanosine and efavirenz.

1 reference

12 December 2020

The first once-daily single-tablet regimen for the treatment of HIV-infected patients

1 reference

12 December 2020

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients

1 reference

12 December 2020

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

1 reference

12 December 2020

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

12 December 2020

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

12 December 2020

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study

1 reference

12 December 2020

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial

1 reference

12 December 2020

Once-daily therapy: Less is more

1 reference

12 December 2020

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

12 December 2020

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

1 reference

12 December 2020

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

12 December 2020

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

1 reference

12 December 2020

A prospective study of predictors of adherence to combination antiretroviral medication

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

10.2165/00003495-200868050-00001

Identifiers

DOI

1 reference

PubMed ID

18370438

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18370438